STING1 and neoplasm: Consequently, systemic administration of STING agonists has the potential to indiscriminately activate STING, leading to cell death in both tumor and non‐tumor tissues.[55, 56] Our study demonstrated that CDH11 was highly expressed in hybrid EMT cells.